David M. Jablons focuses on Cancer research, Wnt signaling pathway, Lung cancer, Immunology and Carcinogenesis. His work carried out in the field of Cancer research brings together such families of science as Cell culture, Apoptosis, Survivin, Beta-catenin and Signal transduction. His research investigates the connection between Wnt signaling pathway and topics such as Cell growth that intersect with problems in Cell biology, RNA interference, PDZ domain and Bioinformatics.
His Lung cancer study integrates concerns from other disciplines, such as Chromosome, Carcinoma, Epidermoid carcinoma and Vaccination. His Carcinoma research is multidisciplinary, incorporating perspectives in Cancer, Growth factor receptor, Surgery and Oncology. His studies in Carcinogenesis integrate themes in fields like Molecular biology, Gene silencing and Antibody.
His main research concerns Cancer research, Lung cancer, Internal medicine, Cancer and Oncology. His Cancer research study combines topics from a wide range of disciplines, such as Mesothelioma, Wnt signaling pathway, Signal transduction, Carcinogenesis and Immunology. His research integrates issues of Molecular biology and Gene silencing in his study of Signal transduction.
His Lung cancer study combines topics from a wide range of disciplines, such as Carcinoma, Surgery, Disease and Adenocarcinoma. His research ties Endocrinology and Internal medicine together. He combines subjects such as Radiology and Chemotherapy with his study of Oncology.
His primary scientific interests are in Cancer research, Lung cancer, Cancer, Internal medicine and Oncology. His Cancer research research is multidisciplinary, incorporating elements of Hippo signaling pathway, Cancer stem cell, Carcinogenesis, non-small cell lung cancer and Metastasis. The subject of his Lung cancer research is within the realm of Pathology.
His Cancer research is multidisciplinary, incorporating perspectives in Molecular biology, Computational biology and DNA sequencing. When carried out as part of a general Internal medicine research project, his work on Stage, Cohort, Clinical trial and Lung cancer staging is frequently linked to work in TNM staging system, therefore connecting diverse disciplines of study. His study on Oncology also encompasses disciplines like
The scientist’s investigation covers issues in Cancer research, Metastasis, Internal medicine, Oncology and Lung cancer. The study incorporates disciplines such as Cancer cell, Cancer, Cancer stem cell, Hippo signaling pathway and non-small cell lung cancer in addition to Cancer research. His Metastasis research includes elements of Carcinogenesis, Cell cycle and Cell migration.
His studies deal with areas such as Tunica vaginalis and Pleural mesothelioma as well as Internal medicine. His studies in Oncology integrate themes in fields like Survival rate, Multimodality Treatment and Aggressive cancer. His Lung cancer research is included under the broader classification of Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
David H. Johnson;Louis Fehrenbacher;William F. Novotny;Roy S. Herbst.
Journal of Clinical Oncology (2004)
Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion
Carolyn M Dresler;Jemi Olak;James E Herndon;William G Richards.
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
Biao He;Liang You;Kazutsugu Uematsu;Keling Zang.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
Miguel Taron;Yukito Ichinose;Rafael Rosell;Tony Mok.
Clinical Cancer Research (2005)
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin Bing S Zhou;Michael Peyton;Biao He;Changnian Liu.
Cancer Cell (2006)
Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes : a possible role for interleukin 6 in cancer cachexia
Andrew S. Greenberg;Richard P. Nordan;Joseph McIntosh;Juan Carlos Calvo.
Cancer Research (1992)
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression
Kazutsugu Uematsu;Biao He;Liang You;Zhidong Xu.
Antitumor activity of recombinant interleukin 6 in mice.
J J Mulé;J K McIntosh;D M Jablons;S A Rosenberg.
Journal of Experimental Medicine (1990)
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.
Josephine Chou;Yu-Ching Lin;Yu-Ching Lin;Yu-Ching Lin;Jae Kim;Liang You.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck (2008)
A Monoclonal Antibody against Wnt-1 Induces Apoptosis in Human Cancer Cells
Biao He;Liang You;Kazutsugu Uematsu;Zhidong Xu.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: